Skip to main content
Header image

Computational system for detection of mutant proteins and SNPs in MS/MS data


Mutations cause a wide spectrum of diseases including cancers. Knowledge of mutation profiles allows scientists and clinicians to understand altered cellular processes and to guide selection of therapies. Screening of alterations is routinely done using modern high-throughput methods such as Single Nucleotide Polymorphism (SNP) chips or Next-Generation Sequencing (NGS). However, mass spectrometry of proteome, method with a great potential in personalized medicine, is not used for this purpose yet.


The technology consists of a computational system, named claire, used for direct detection of mutant and polymorphic proteins in MS/MS data. At its core, the system holds large protein variant database, used to match MS/MS spectra. The reliability of detection is based on our probabilistic algorithm (Patent pending, EP 18184710.4), which was verified under variety of circumstances. Furthermore, given high computational efficiency of the algorithm and modularity of the software design, the system can be easily adapted to novel circumstances. For instance, the system was recently improved to identify intact variant N-glycopeptides, utilizing the same detection principles.

Advantages over existing solutions

The software allows to advance mass spectrometer into a tool for reading of mutations and polymorphisms. This type of information is critical not only in cancer research but can be also used for other applications. For instance, our analyses have shown the capacity to authenticate cell lines or identify individuals from high-resolution MS/MS spectral data. Another advantage is the potential to directly observe effect of mutation on post-translational modifications.

Patent protection

EP 18184710.4

Technology IP owners

Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc.

Commercial offer

Exclusive or non-exclusive license to the software


More information is available upon signing a CDA/NDA. Please contact IMTM´s director ( or the technology transfer office (